Thursday 26 May 2016

Facebook and Microsoft are building an undersea cable to move massive amounts of data much faster.


Mark Zuckerberg question mark
Facebook and Microsoft are teaming up to build a new underwater cable that will span more than 4,000 miles across the Atlantic Ocean, according to a new announcement.
The cable will help both companies transfer more data more quickly between the US and Europe, connecting hubs in northern Virginia and Bilbao, Spain.
The move is meant to make Microsoft's and Facebook's services work more quickly and reliably for overseas users.
Telecommunications companies are usually the ones building massive undersea infrastructure like this, but as the data needs of tech giants grow they want to take greater control over the networks they rely on. For example, Google teamed up with five Asian telecom companies to fund a $300 million underwater cable network connecting the US and Japanin 2014.
Facebook has a slew of other initiatives to redesign telecommunications infrastructure, including tech to make radio towers more efficient and a wireless system tailored for dense urban areas.
The duo is calling its project MAREA, and construction will begin in August and end in October 2017.
Though the two tech giants are collaborating on the cable, it will beoperated and managed by the telecommunications-infrastructure company Telxius.

Antidepressants no longer prescribed only for depression.

Doctors prescribe antidepressants for a wide range of medical problems other than depression, apparently fuelling the boom in sales of these medications, researchers report.
'Off-label' conditions
Depression accounts for only a little more than half the antidepressant prescriptions issued by Quebec physicians during the past decade, the Canadian study found.
Doctors also issued antidepressants to treat anxiety, insomnia, chronic pain, panic disorders, fibromyalgia, migraine, obsessive-compulsive disorders, and a host of other "off-label" conditions for which the drugs are not approved, according to the report.
Two out of every three non-depression prescriptions for antidepressants were handed out under an off-label purpose, the findings showed.
"The thing that's of concern here is that when prescribing for conditions other than depression, often these are for indications such as fibromyalgia and migraine where it's unknown whether the drug is going to be effective, because it's never been studied," said senior author Robyn Tamblyn. She is a professor of epidemiology and biostatistics at McGill University in Montreal. "These doctors are prescribing in the dark," she said.
Antidepressant use in the United States increased almost 400 percent between 1988-1994 and 2005-2008, with the most recent figures showing 11 percent of teens and adults take antidepressants, according to the U.S. Centres for Disease Control and Prevention.
Researchers have suspected part of this boom may be that doctors are prescribing antidepressants for off-label indications that haven't been evaluated by the U.S. Food and Drug Administration, Tamblyn said.
Unapproved for other conditions
To investigate, Tamblyn and her colleagues gathered electronic medical records generated by primary care physicians in Quebec between 2006 and 2015.
During that period, about 102,000 antidepressant prescriptions were written by 158 physicians for nearly 120,000 patients, the investigators found.
Only 55 percent of antidepressant prescriptions were handed out to treat depression, the researchers said.
Other illnesses treated with antidepressants included: anxiety disorders (18.5 percent); insomnia (10 percent); chronic pain (6 percent); and panic disorders (4 percent).
In several conditions listed, no antidepressant has ever been approved for their treatment, the researchers noted. These include migraine, menopause, attention-deficit/hyperactivity disorder and digestive system disorders.
Other conditions treated with antidepressants included sexual dysfunction, premenstrual syndrome, post-traumatic stress disorder, urinary problems and bulimia.
Depression expert Dr Peter Kramer said antidepressants have a wide range of potential uses, given how they work.
"I've always written these are not necessarily best called antidepressants," said Kramer, a clinical professor emeritus of psychiatry and human behaviour at Brown University in Providence, Rhode Island.
A developed tradition
"They are active in the nervous system, but whether they reverse depression or they intervene against certain kinds of injuries against nerve cells in some general way that isn't targeting depression, that seems to be an open question," added Kramer, who wasn't involved in the study.
Some doctors use a sedating antidepressant called Trazodone to counter insomnia in addicts weaning themselves off drugs, Kramer said. Others have used low doses of tricyclic antidepressants, such as amitriptyline to treat chronic pain.
"I'm a little more sceptical about broad-brush research results that make doctors look as if they are foolish," Kramer said. "I like to start with the presumption that something thoughtful is going on, and try to figure out what that is."
However, some off-label antidepressant use might be occurring out of a developed tradition, rather than any practical or scientific knowledge, said the study's lead author, Jenna Wong, a researcher at McGill.
"They've become well-known off-label uses for these drugs in the medical community," Wong said. "It's kind of like a culture among doctors. You see your colleague prescribing it, and then you would be more likely to."
Kramer and Tamblyn agreed that clinical trials need to be performed on these off-label uses for antidepressants, to either prove or rule out the drugs' effectiveness.
"If doctors are using medicines in these areas, we should do more formal research on those areas," Kramer said.
In the future, depression researchers have to keep in mind that antidepressant prescriptions are not a good way to track the mood disorder, since half of the time these drugs are aimed at treating other conditions, he added.
In other words, "we shouldn't use antidepressant prescribing as a proxy for depression," Kramer said.

Balloon-in-a-pill the latest way to curb obesity.

A new ingestible and inflatable balloon system seems to be a non-invasive way to fill up the stomach and curb appetite, researchers report.
Patients ingest three capsules
The balloon system, known as Obalon, helped obese people lose nearly 7 percent of their body weight, the investigators added.
So, how exactly does such as system work?
"Patients swallow a capsule containing a balloon tethered to a small catheter," said study author Dr Shelby Sullivan, director of bariatric endoscopy at Washington University School of Medicine in St. Louis.
"Once it's reached the stomach, we inflate the balloon with a nitrogen mixed gas," Sullivan said.
Patients ingest three capsules in all: the second at three weeks, and a third at either week nine or 12. When expanded, each balloon holds about a cup of gas (750 cubic centimeters in all) to fill the stomach and reduce eating urges, the researchers explained.
At six months, all balloons are removed through an outpatient procedure (endoscopy), in which a flexible tube is inserted through the mouth and into the stomach.
"Because there's no incision and no breaking of the skin we don't think of it as 'invasive'," said Sullivan. Removal takes about 16 minutes, she added.
A second balloon system
Obalon is not yet approved by the U.S. Food and Drug Administration. Ongoing studies to assess its benefits have been funded by the system's manufacturer, Obalon Therapeutics. A second balloon system, known as Elipse, is also being tested in ongoing trials.
Sullivan and her colleagues are to present their findings at the Digestive Disease Week meeting in San Diego. Findings presented at meetings are generally viewed as preliminary until published in a peer-reviewed journal.
Nearly 79 million Americans adults are considered obese, according to the U.S. Centres for Disease Control and Prevention. Obesity is defined as a body mass index (BMI) of 30 or higher. BMI is a rough estimate of body fat based on height and weight measurements.
There are a number of invasive treatment options for those struggling with "extreme obesity" (a BMI of 40 or higher), such as gastric bypass surgery. For those in the BMI range of 30 to 40, adjustable gastric banding (AGB) is an option, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.
The Elipse system entails swallowing just one balloon that is then filled with distilled water, rather than gas. After four months, that balloon automatically deflates and is naturally excreted, without endoscopic removal.
For the Obalon trials, 366 obese patients were divided into two groups. Half swallowed three Obalon balloons; the other half swallowed three sugar (placebo) capsules. The volunteers were between 22 and 64 years old.
A 'step forward'
Over six months, the placebo group lost 3.6 percent of their weight, on average, compared with 6.8 percent among the Obalon patients. And nearly two-thirds of the Obalon group lost at least 5 percent of their weight, compared to just a third of the placebo group, the study showed.
Sullivan characterized the Obalon as a "step forward", compared with currently available gastric balloons.
"Current balloons require giving patients a lot of anti-nausea and anti-spasmodic medications," she explained. "The Obalon is a lot better tolerated. And while current balloons prompt 80 percent of their weight loss in the first three months before trailing off, we didn't see any slow-down over time in the rate of weight loss with the Obalon."
Sullivan said it would be hard to estimate the cost of the new system right now. She acknowledged that it's unlikely to be immediately covered by insurance.
"But, assuming it's the same price as the other balloon systems at my own institution, I would guess it would probably be somewhere around $1,500 (±R23 000)," she said.
Potentially truly revolutionary
She added that the Obalon could be available by the end of the year, and so is "much farther along in the development process" than the Elipse.
Dr John Morton, past president of the American Society for Metabolic and Bariatric Surgery, and chief of bariatric and minimally invasive surgery at Stanford University in California, said the Elipse system may eventually have a leg up on Obalon.
"I think the Elipse is potentially truly revolutionary because it's something that you can swallow and, unlike the Obalon, excrete on your own," he said. "And the other issue is that saline balloons always do better than air balloons, which not everyone can easily swallow.
"But the Obalon system has been available overseas for years, particularly in Mexico, and have been placed with some frequency," Morton acknowledged. "And there haven't been any head-to-head comparisons, so it's hard to make a scientific assessment until we do that."